Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomised phase III trial.

Arnaud ConstantinRoberto CaporaliChristopher J EdwardsJoão Eurico FonsecaFlorenzo IannoneEdward KeystoneHendrik Schulze-KoopsTaek KwonSeungmin KimSangWook YoonDong-Hyeon KimGahee ParkDae Hyun Yoo

Published in: Rheumatology (Oxford, England) (2022)

ClincialTrials.gov, http://clinicaltrials.gov, NCT03147248.

Keyphrases

phase iii
open label
clinical trial
rheumatoid arthritis
double blind
placebo controlled
phase ii
study protocol
disease activity
high dose
ulcerative colitis
ankylosing spondylitis
interstitial lung disease
randomized controlled trial
low dose
systemic lupus erythematosus